Estimating the money flow in the economy attributed to rotavirus disease and vaccination in the Netherlands using a Social Accounting Matrix (SAM) framework-Reference-Cited by-同舟云学术

Estimating the money flow in the economy attributed to rotavirus disease and vaccination in the Netherlands using a Social Accounting Matrix (SAM) framework

Published:2019-11-22 Issue:6 Volume:20 Page:603-612
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Kotsopoulos Nikolaos¹²,Haitsma Gertruud¹,Connolly Mark P.¹³^ORCID,Standaert Baudouin⁴^ORCID

Affiliation:

1. Health Economics, Global Market Access Solutions Sarl, St-Prex, Switzerland

2. Department of Economics, University of Athens, Athens, Greece

3. Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands

4. Research & Development, GSK, Wavre, Belgium

Funder

GlaxoSmithKline Biologicals S.A.

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2020.1693269

Reference41 articles.

1. Global Review of the Age Distribution of Rotavirus Disease in Children Aged <5 Years Before the Introduction of Rotavirus Vaccination

2. A review of recommendations for rotavirus vaccination in Europe: Arguments for change

3. Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination

4. The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands

5. Dissecting the indirect effects caused by vaccines into the basic elements

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Knowledge and Application of Economics in Healthcare in a High-Income Country Today: The Case of Belgium;Journal of Market Access & Health Policy;2024-09-04

2. Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework;Expert Review of Pharmacoeconomics & Outcomes Research;2024-01-23

3. Investing in the Prevention of Communicable Disease Outbreaks: Fiscal Health Modelling—The Tool of Choice for Assessing Public Finance Sustainability;Vaccines;2023-04-10

4. Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella;PharmacoEconomics;2023-02-21

5. The Value of Rotavirus Vaccination in Europe: A Call for Action;Infectious Diseases and Therapy;2022-11-10